Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other ...

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low.

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Hyderabad-based Natco Pharma has filed a lawsuit against Danish drugmaker Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy (semaglutide), before the Delhi High Court.

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

NEW YORK - August 20, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Novo ... and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and ...

Twice as many employers as last year say they are planning to pull back on filling jobs, according to a new Conference Board survey.

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.